Donanemab (Kisunla)

Type: drug

Status: FDA Approved. EU: Delayed/Restricted.

Developer: Eli Lilly

Breakthrough Summary

No summary available.

Mechanism of Action

Anti-amyloid antibody that clears amyloid plaques from brain

Year: 2024